Basic Information
| LncRNA/CircRNA Name | CRALA |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR etc. |
| Sample | breast tissues |
| Expression Pattern | up-regulated |
| Function Description | CRALA is upregulated in chemoresistant breast cancer cell lines compared to their parental lines. Silencing of CRALA in chemoresistant breast cancer cells resensitizes the cells to chemotherapy in vitro. Furthermore, univariate and multivariate analysis showed that higher CRALA expression was significantly associated with poor prognosis in 144 breast cancer patients. |
| Pubmed ID | 28834648 |
| Year | 2017 |
| Title | Long non-coding RNA CRALA is associated with poor response to chemotherapy in primary breast cancer |
External Links
| Links for CRALA | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |